Clinical Trial

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Protocol Amendment History 1 change
minor Completion pushed: 2027-03 -> 2028-03 2026-07-09
Trial Details
NCT Number NCT04328844
Lead Sponsor iOnctura
Conditions Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
Enrollment 210 participants
Start Date 2020-02-25
Primary Completion 2023-12-13 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-08